CAMBRIDGE, Mass., Oct. 03, 2017 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:
Tuesday, October 10, 2017
Chardan Gene Therapy Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences & eXtellia
Location: New York, New York
Presentation Time: 2:45 pm EDT
Thursday, October 12, 2017
Jefferies Gene Therapy and Editing Summit
Who: Nessan Bermingham, Ph.D., President, Chief Executive Officer and Founder
Location: New York, New York
Presentation Time: 1:40 pm EDT
A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Intellia Contacts:
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs
& Communications
+1 857-706-1071
[email protected]
Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
[email protected]


China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
OpenAI Addresses Security Vulnerability in macOS App Certification Process
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 



